Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Tegaserod in Women With Dyspepsia
NCT00232037Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tegaserod in dyspepsia, sponsored by Novartis. Primary endpoint: Long term safety at 6 months. Started Sep 2004; status: completed.
02
Drugs
tegaserod
03
Conditions
dyspepsia
Beyond the preview
Go deeper on NCT00232037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232037.